Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder

Objectives: Escitalopram (S-CT) is used widely to treat patients with panic disorder (PD) and the CYP2C19 enzyme is responsible for S-CT metabolism. We hypothesized that CYP2C19 polymorphisms were associated with S-CT treatment response in Chinese patients with PD. Patients and methods: Seventy-eight patients with PD completed the assessment by the Panic Disorder Severity Scale – Chinese Version (PDSS-CV) and the Hamilton Anxiety Scale (HAMA-14) during an 8-week period. All patients were administered a fixed dose of 10 mg/day S-CT. Three CYP2C19 metabolizer phenotypes were analyzed by PCR-genotyping microarray, including extensive metabolizer (EM), intermediate metabolizer, and poor metabolizer (PM). Results: This prospective, open-label and observational study showed that the proportion of EM (43.6%) was higher than that of PM (10.2%). There were higher response ratios of PDSS-CV in PM (the second to fourth week: 62.5–100%) than in EM (the second to fourth week: 23.5–55.9%) (Ps

from Genetics via xlomafota13 on Inoreader http://ift.tt/2upKRzL
via IFTTT